Who
Paula A. Johnson
Director
Company insider
Files Form 4 as: Director, Maze Therapeutics; Director, Johnson & Johnson; Director, Abiomed; Director, Mirror Merger Sub 2; Director, West Pharmaceutical Services.
In numbers
- Trades disclosed
- 76
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.1M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 2 May 2006
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 13 Aug 2026filed 17 Aug 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —975 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —975 at $0.00 | filing |
| 24 Apr 2025filed 28 Apr 2025 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,316 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,385.7 at $0.00 | filing |
| 23 Aug 2023filed 28 Jan 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code D | —11 at $0.00 | filing |
| 27 Apr 2023filed 2 May 2023 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,429.5 at $0.00 | filing |
| 22 Dec 2022filed 27 Dec 2022 | Abiomed | SEC FORM 4 Code D | —1,659 at $0.00 | filing |
| 11 Aug 2022filed 12 Aug 2022 | Abiomed | SEC FORM 4 Code F | $77K263 at $293.34 | filing |
| 10 Aug 2022filed 12 Aug 2022 | Abiomed | SEC FORM 4 Code A | —681 at $0.00 | filing |
| 26 Apr 2022filed 29 Apr 2022 | Abiomed | SEC FORM 4 Code F | $31K101 at $302.14 | filing |
| 11 Aug 2021filed 13 Aug 2021 | Abiomed | SEC FORM 4 Code A | —625 at $0.00 | filing |
| 26 Apr 2021filed 28 Apr 2021 | Abiomed | SEC FORM 4 Code A | —717 at $0.00 | filing |
| 1 Mar 2021filed 3 Mar 2021 | Mirror Merger Sub 2option or derivative | SEC FORM 4 Code D | $426K5,840 at $73.00 | filing |
| 12 Feb 2021filed 16 Feb 2021 | Eaton Vanceoption or derivative | SEC FORM 4 Code A | —31 at $0.00 | filing |
| 18 Dec 2020filed 18 Dec 2020 | Eaton Vanceoption or derivative | SEC FORM 4 Code A | —347 at $0.00 | filing |
| 13 Nov 2020filed 17 Nov 2020 | Eaton Vanceoption or derivative | SEC FORM 4 Code A | —20 at $0.00 | filing |
| 2 Nov 2020filed 4 Nov 2020 | Eaton Vanceoption or derivative | SEC FORM 4 Code A | —2,317 at $0.00 | filing |
| 1 Nov 2020filed 3 Nov 2020 | Eaton Vanceoption or derivative | SEC FORM 4 Code A | —20 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.